Trial Registration International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD420251019235 Keywords: cardiovascular outcomes, chronic kidney disease, GLP1 receptor agonist, major adverse cardiovascular events, major kidney adverse events, metaanalysis, renal outcomes, semaglutide, type 2 diabetes mellitus Semaglutide offers dual kidney and heart protection in patients with chronic kidney disease
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6, PubMed)
Healthcare providers must remain vigilant and closely monitor this potentially life-threatening adverse event
GLP-1 Sidekick generates personalized meal ideas based on your symptoms and medication
09 dated 19/05/2022) and by the Ethical Committees of all participating Centers, and conducted according to the principles of the Declaration of Helsinki
It can raise estrogen levels, which fuel certain hormone-related cancers, increase insulin and insulin-like growth factors that help tumors grow, and drive chronic inflammation that creates an environment where cancer is more likely to develop and spread
